SCHEMBL25166294

SCHEMBL25166294

Fc1ccc2c(c1Br)OCCO2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
HTT P42858 3/20 0.38
MAPT P10636 1/20 0.38
BLM P54132 1/20 0.38
EGFR P00533 2/20 0.38
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
MAOB P27338 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
P4HB P07237 1/20 0.33
CRHBP P24387 2/20 0.32
CRHR2 Q13324 2/20 0.32
PKM P14618 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049221 0.83 AOC3 (0.42) LMNAHTTMAOBNPC1RAB9A
SCHEMBL25166479 0.83 AOC3 (0.42) LMNAHTTMAOBNPC1RAB9A
SCHEMBL28892534 0.76 MEN1 (0.33) LMNAHTTMAPTBLMITGB2
SCHEMBL30002318 0.76 MEN1 (0.33) LMNAHTTMAPTBLMITGB2
SCHEMBL2026290 0.75 LMNA (0.38) LMNAHTTMAPTBLMEGFR
SCHEMBL23870266 0.75 ADRA2A (0.44) LMNAHTTITGB2ICAM1ITGAL
SCHEMBL25166334 0.75 LMNA (0.38) LMNAHTTMAPTBLMEGFR
SCHEMBL22827024 0.75 MAPT (0.38) LMNAHTTMAPTBLMITGB2
SCHEMBL25166705 0.75 HTT (0.38) LMNAHTTMAPTBLMITGB2
SCHEMBL30329793 0.75 LMNA (0.38) LMNAHTTMAPTBLMEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119954793-A Compounds as xanthine oxidase inhibitors and uses thereof 广州市联瑞制药有限公司 2025-05-09 CN disclosed
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 LMNA 3664/4885HTT 673/4885MAPT 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.